Accepted Manuscript

Mutation analysis of therapy-related myeloid neoplasms

Takahiro Nishiyama, Yuichi Ishikawa, Naomi Kawashima, Akimi Akashi, Yoshiya Adachi, Hikaru Hattori, Yoko Ushijima, Hitoshi Kiyoi

 PII:
 S2210-7762(18)30004-8

 DOI:
 10.1016/j.cancergen.2018.02.006

 Reference:
 CGEN 583



To appear in: Cancer Genetics

Received date:5 January 2018Revised date:17 February 2018Accepted date:21 February 2018

Please cite this article as: Takahiro Nishiyama, Yuichi Ishikawa, Naomi Kawashima, Akimi Akashi, Yoshiya Adachi, Hikaru Hattori, Yoko Ushijima, Hitoshi Kiyoi, Mutation analysis of therapy-related myeloid neoplasms, *Cancer Genetics* (2018), doi: 10.1016/j.cancergen.2018.02.006

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Highlights

- *t*-MN cells preferentially acquired *TP53* and epigenetic modifying genes mutations.
- A somatic *TET2* mutation was identified in the normal PB at the disease-free period.
- A germ-line *MYB* mutation was identified in a patient who developed MDS after FL.

ACERTICA

Download English Version:

https://daneshyari.com/en/article/8433654

Download Persian Version:

https://daneshyari.com/article/8433654

Daneshyari.com